Authors
Andrew Brown, Carmel Armon, Paul Barkhaus, Morgan Beauchamp, Tulio Bertorini, Mark Bromberg, Javier Mascias Cadavid, Gregory T Carter, Jesse Crayle, Eva L Feldman, Terry Heiman-Patterson, Sartaj Jhooty, Alexandra Linares, Xiaoyan Li, Elise Mallon, Christopher Mcdermott, Tasnim Mushannen, George Nathaniel, Gary Pattee, Kaitlyn Pierce, Dylan Ratner, Lenka Slactova, Paul Wicks, Richard Bedlack
Publication date
2024/4/2
Source
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume
25
Issue
3-4
Pages
416-419
Publisher
Taylor & Francis
Description
ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review insulin, which has at least one plausible mechanism for slowing ALS progression. However, pre-clinical studies are limited and there have been no trials in PALS yet. Insulin use in patients without a metabolic need may cause very serious and potentially lethal side effects. While further studies to evaluate potential benefits may be warranted, at this time we cannot endorse insulin treatment to slow ALS progression.
Scholar articles
A Brown, C Armon, P Barkhaus, M Beauchamp… - Amyotrophic Lateral Sclerosis and Frontotemporal …, 2024